Business
Initial Stereax M300 Shipments
Ilika plc has commenced shipping prototype Stereax M300 solid-state batteries to 21 customers, marking a significant commercial milestone and progressing its 10-year manufacturing agreement with Cirtec Medical. These initial deliveries are intended for testing in active implantable medical devices, including implanted sensors and neurostimulators, with the goal of gathering data for a market estimated at over $40 billion. The company anticipates soliciting feedback from this core customer group before ramping up production, leveraging Cirtec Medical's manufacturing capabilities in Lowell, Massachusetts. Disclaimer*
About this update from Ilika Plc
[{"type":"text","content":"\n\n18 December 2025\nIlika plc\n('Ilika,' the 'Company,' or the 'Group')\n \nIlika Announces Initial Stereax M300 Shipments\n \nCommencement of Shipping Marks Important Commercial Milestone\n \nIlika (AIM: IKA), the UK pioneer in solid state battery technology, announces it has commenced shipping prototype Stereax M300s to customers, meeting an important commercial milestone.\n \nThese initial deliveries will be allocated to the 21 customers which form Ilika's existing order book, many of whom have previously received Stereax batteries for evaluation from the Company's UK pilot line. A number of batteries from the initial batches will be allocated to the extensive M300 testing programme, which is designed to generate a larger body of test data relevant to exciting applications in active implantable medical devices (AIMDs). Applications include powering implanted sensors, neurostimulators, orthopaedic implants, orthodontic wearables and ophthalmology devices. With its small footprint and enhanced charging capabilities, Stereax is ideally suited to meet the needs of AIMDs, offering benefits that include: reduced surgery time, the ability to place the implant closer to the point of therapy, long-lasting performance, user recharging at home and the ability to power Bluetooth radio. Ilika and its strategic partner, Cirtec Medical Corp, will solicit feedback from this core customer group to verify customer experience before ramping production.\n \nThis milestone progresses the 10-year manufacturing agreement signed in August 2023, in which Cirtec Medical, a leading US medical device manufacturer, will produce Ilika's Stereax battery portfolio.\n \nDaniel Weinstein, Co-Founder and Chief Executive Officer at Lura Health, a provider of non-invasive health management solutions using continuous salivary monitoring, said: \"As one of the first customers to receive M300 prototypes, we are excited to be working with Ilika and Cirtec Medical to demonstrate the deployment of Stereax miniature batteries in our range of non-invasive microsensors for salivary health markers.\"\n \nShawn Martin, Vice President at Cirtec Medical, said: \"The Stereax product is an excellent addition to our world-leading capabilities in advanced miniaturised electronics designed for life-changing medical devices.\"\n \nGraeme P...